257 related articles for article (PubMed ID: 36762794)
21. Cytotoxic T lymphocyte-associated protein 4 antibody aggrandizes antitumor immune response of oncolytic virus M1 via targeting regulatory T cells.
Liu W; Liu Y; Hu C; Xu C; Chen J; Chen Y; Cai J; Yan G; Zhu W
Int J Cancer; 2021 Sep; 149(6):1369-1384. PubMed ID: 34086978
[TBL] [Abstract][Full Text] [Related]
22. PD-1
Kamada T; Togashi Y; Tay C; Ha D; Sasaki A; Nakamura Y; Sato E; Fukuoka S; Tada Y; Tanaka A; Morikawa H; Kawazoe A; Kinoshita T; Shitara K; Sakaguchi S; Nishikawa H
Proc Natl Acad Sci U S A; 2019 May; 116(20):9999-10008. PubMed ID: 31028147
[TBL] [Abstract][Full Text] [Related]
23. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
24. IL2/Anti-IL2 Complex Combined with CTLA-4, But Not PD-1, Blockade Rescues Antitumor NK Cell Function by Regulatory T-cell Modulation.
Caudana P; Núñez NG; De La Rochere P; Pinto A; Denizeau J; Alonso R; Niborski LL; Lantz O; Sedlik C; Piaggio E
Cancer Immunol Res; 2019 Mar; 7(3):443-457. PubMed ID: 30651291
[TBL] [Abstract][Full Text] [Related]
25. Dual targeting of CTLA-4 and CD47 on T
Zhang A; Ren Z; Tseng KF; Liu X; Li H; Lu C; Cai Y; Minna JD; Fu YX
Sci Transl Med; 2021 Aug; 13(605):. PubMed ID: 34349035
[TBL] [Abstract][Full Text] [Related]
26. Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects.
Ruocco MG; Pilones KA; Kawashima N; Cammer M; Huang J; Babb JS; Liu M; Formenti SC; Dustin ML; Demaria S
J Clin Invest; 2012 Oct; 122(10):3718-30. PubMed ID: 22945631
[TBL] [Abstract][Full Text] [Related]
27. Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?
Ohue Y; Nishikawa H
Cancer Sci; 2019 Jul; 110(7):2080-2089. PubMed ID: 31102428
[TBL] [Abstract][Full Text] [Related]
28. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses.
Tuve S; Chen BM; Liu Y; Cheng TL; Touré P; Sow PS; Feng Q; Kiviat N; Strauss R; Ni S; Li ZY; Roffler SR; Lieber A
Cancer Res; 2007 Jun; 67(12):5929-39. PubMed ID: 17575163
[TBL] [Abstract][Full Text] [Related]
29. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
30. CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells.
Zhou J; Bashey A; Zhong R; Corringham S; Messer K; Pu M; Ma W; Chut T; Soiffer R; Mitrovich RC; Lowy I; Ball ED
Biol Blood Marrow Transplant; 2011 May; 17(5):682-92. PubMed ID: 20713164
[TBL] [Abstract][Full Text] [Related]
31. Treg-mediated acquired resistance to immune checkpoint inhibitors.
Saleh R; Elkord E
Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
[TBL] [Abstract][Full Text] [Related]
32. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
Okuyama K; Naruse T; Yanamoto S
J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
[TBL] [Abstract][Full Text] [Related]
33. Construction of self-recognizing regulatory T cells from conventional T cells by controlling CTLA-4 and IL-2 expression.
Yamaguchi T; Kishi A; Osaki M; Morikawa H; Prieto-Martin P; Wing K; Saito T; Sakaguchi S
Proc Natl Acad Sci U S A; 2013 Jun; 110(23):E2116-25. PubMed ID: 23690575
[TBL] [Abstract][Full Text] [Related]
34. TCR Signaling and CD28/CTLA-4 Signaling Cooperatively Modulate T Regulatory Cell Homeostasis.
Holt MP; Punkosdy GA; Glass DD; Shevach EM
J Immunol; 2017 Feb; 198(4):1503-1511. PubMed ID: 28053234
[TBL] [Abstract][Full Text] [Related]
35. Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
Horn LA; Long TM; Atkinson R; Clements V; Ostrand-Rosenberg S
Cancer Immunol Res; 2018 Jan; 6(1):59-68. PubMed ID: 29122838
[TBL] [Abstract][Full Text] [Related]
36. CD86 Is a Selective CD28 Ligand Supporting FoxP3+ Regulatory T Cell Homeostasis in the Presence of High Levels of CTLA-4.
Halliday N; Williams C; Kennedy A; Waters E; Pesenacker AM; Soskic B; Hinze C; Hou TZ; Rowshanravan B; Janman D; Walker LSK; Sansom DM
Front Immunol; 2020; 11():600000. PubMed ID: 33363541
[TBL] [Abstract][Full Text] [Related]
37. Leveraging the Treg-intrinsic CTLA4-PKCη signaling pathway for cancer immunotherapy.
Liu HY; Pedros C; Kong KF; Canonigo-Balancio AJ; Xue W; Altman A
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34588224
[TBL] [Abstract][Full Text] [Related]
38. Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells.
Shimauchi T; Kabashima K; Tokura Y
Cancer Sci; 2008 Jan; 99(1):98-106. PubMed ID: 17970785
[TBL] [Abstract][Full Text] [Related]
39. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma.
Ghatalia P; Zibelman M; Geynisman DM; Plimack ER
Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995
[TBL] [Abstract][Full Text] [Related]
40. CTLA-4 blockade enhances antitumor immunity of intratumoral injection of immature dendritic cells into irradiated tumor in a mouse colon cancer model.
Son CH; Bae JH; Shin DY; Lee HR; Choi YJ; Jo WS; Ho Jung M; Kang CD; Yang K; Park YS
J Immunother; 2014 Jan; 37(1):1-7. PubMed ID: 24316550
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
